RSV patients treated with antiviral drug S-337395 showed statistically significant reduction in viral load S-337395 is ...

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS Newswire / Febru ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a biotechnology company focused on developing small molecule drugs for viral infections and liver diseases, is navigating a critical phase in its evolution.

Respiratory syncytial virus (RSV), or human respiratory syncytial virus (hRSV), is a common viral respiratory infection that triggers mild, cold-like symptoms. However, at-risk populations ...

A nationwide surge in flu, COVID-19, RSV and norovirus infections is fueling concerns of a possible virus "quademic." Or is it just winter? The three respiratory viruses plus norovirus ...

LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...

(Sharecast News) - hVIVO reported positive results from a phase 2a respiratory syncytial virus (RSV) human challenge trial conducted on behalf of Shionogi on Wednesday. The AIM-traded firm said ...

The trial demonstrated a significant reduction in viral load for Shionogi's investigational oral RSV antiviral candidate, S-337395. S-337395, which has received Fast Track designation from the U.S ...